HSBC/CALL/MODERNA/400/0.1/15.01.25 | Market Closed - Bid/Ask 15:35:20 2024-06-28 EDT | After market 15:57:54 | |||
| 0.01 EUR | -44.44% |
|
0.018 | +80.00% |
| Current month | -66.67% | ||
| 1 month | -81.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.01 | -44.44% |
| 24-06-27 | 0.018 | -14.29% |
| 24-06-26 | 0.021 | -32.26% |
| 24-06-25 | 0.031 | -8.82% |
| 24-06-24 | 0.034 | +9.68% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 03:35 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG807T |
| ISIN | DE000HG807T4 |
| Date issued | 2023-02-02 |
| Strike | 400 $ |
| Maturity | 2025-01-15 (201 Days) |
| Parity | 10 : 1 |
| Emission price | 1.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.34 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.015 € |
| Spread % | 60.00% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
145.9
USD
Spread / Average Target
+20.36%
- Stock Market
- Warrants
- Warrant
